We provide you with 20 years of free, institutional-grade data for ALPN stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ALPN. Explore the full financial landscape of ALPN stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| PENG STANFORD L | Derivatives Exercise | 271,792 | 2024-05-10 | ||
| FUHS ULRICH MARTIN | Derivatives Exercise | 22,820 | 2024-05-10 | ||
| DURAND REMY | Derivatives Exercise | 95,288 | 2024-05-10 | ||
| GOLD MITCHELL | Derivatives Exercise | 13,245 | 2024-05-10 | ||
| Rickey James Paul | Derivatives Exercise | 26,761 | 2024-05-09 | ||
| Topper James N | Sale | -19 | $64.57 | $1,227 | 2024-04-29 |
| FUHS ULRICH MARTIN | Initial | 2024-04-05 | |||
| Rickey James Paul | Sale | -118,000 | $22 | $2,596,000 | 2024-01-29 |
| Rickey James Paul | Derivatives Exercise | 118,000 | 2024-01-29 | ||
| GOLD MITCHELL | Grant, award...etc | 96,000 | 2024-01-05 | ||
| PENG STANFORD L | Grant, award...etc | 48,000 | 2024-01-05 | ||
| DURAND REMY | Grant, award...etc | 31,200 | 2024-01-05 | ||
| Rickey James Paul | Grant, award...etc | 31,200 | 2024-01-05 | ||
| GOLD MITCHELL | Sale | -48,264 | $19.65 | $948,388 | 2023-12-29 |
| GOLD MITCHELL | Derivatives Exercise | 74,441 | 2023-12-29 | ||
| GOLD MITCHELL | Sale | -1,016 | $20.04 | $20,362 | 2023-12-29 |
| GOLD MITCHELL | Derivatives Exercise | 1,016 | 2023-12-29 | ||
| ORBIMED ADVISORS LLC | Sale | -161,216 | $19.96 | $3,217,871 | 2023-12-29 |
| ORBIMED ADVISORS LLC | Sale | -1,385,131 | $19.96 | $27,647,215 | 2023-12-29 |
| Thompson Peter A. | Sale | -161,216 | $19.96 | $3,217,871 | 2023-12-29 |
| Thompson Peter A. | Sale | -1,385,131 | $19.96 | $27,647,215 | 2023-12-29 |
| GOLD MITCHELL | Sale | -91,884 | $20.43 | $1,876,777 | 2023-12-27 |
| GOLD MITCHELL | Derivatives Exercise | 91,884 | 2023-12-27 | ||
| GOLD MITCHELL | Sale | -2,402 | $20.01 | $48,064 | 2023-12-21 |
| GOLD MITCHELL | Derivatives Exercise | 2,402 | 2023-12-21 | ||
| Rickey James Paul | Sale | -15,213 | $19.21 | $292,222 | 2023-12-21 |
| Rickey James Paul | Derivatives Exercise | 15,213 | 2023-12-21 | ||
| Rickey James Paul | Sale | -58,787 | $19 | $1,116,982 | 2023-12-18 |
| Rickey James Paul | Derivatives Exercise | 58,787 | 2023-12-18 | ||
| GOLD MITCHELL | Derivatives Exercise | 8,613 | 2023-12-12 | ||
| GOLD MITCHELL | Sale | -118,000 | $17.08 | $2,015,428 | 2023-12-12 |
| Rickey James Paul | Sale | -70,811 | $16.06 | $1,137,111 | 2023-12-06 |
| Rickey James Paul | Derivatives Exercise | 70,811 | 2023-12-06 | ||
| Rickey James Paul | Sale | -700 | $16 | $11,200 | 2023-12-01 |
| Rickey James Paul | Derivatives Exercise | 700 | 2023-12-01 | ||
| Decheng Capital Global Healthcare Fund (Master), LP | Open Market Purchase | 375,000 | $12.5 | 2023-11-14 | |
| Cui Xiangmin | Open Market Purchase | 375,000 | $12.5 | 2023-11-14 | |
| Rickey James Paul | Sale | -18,003 | $16.03 | $288,554 | 2023-11-08 |
| Rickey James Paul | Derivatives Exercise | 10,989 | 2023-11-08 | ||
| DURAND REMY | Initial | 2023-04-27 | |||
| Cui Xiangmin | Grant, award...etc | 2,000,000 | $7.35 | 2022-09-27 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | Grant, award...etc | 1,360,544 | $7.35 | 2022-09-27 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | Grant, award...etc | 639,456 | $7.35 | 2022-09-27 | |
| Venkatesan Jay | Derivatives Exercise | 20,063 | 2022-07-19 |
The information provided in this report about ALPN stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Alpine Immune Sciences, Inc(NASDAQ:ALPN) 
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline include ALPN-101, an inducible T cell costimula...
Website: http://www.alpineimmunesciences.com
Founded: 2007
Full Time Employees: 53
Sector: Healthcare
Industry: Biotechnology